Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 134 for “"P2Y12"”.
-
Understanding the pharmacological consequence of functional P2Y1- P2Y12 heterodimerisation
… to understand receptor dynamics. The P2Y1 and P2Y12 receptors belong to the class A family of GPCRs and are widely expressed throughout the body. There is growing evidence that purinergic receptors also exist as oligomers. Previously, the Kennedy lab proposed the formation of a constitutive …
-
Identifizierung und Charakterisierung essentieller Aminosäuren im humanen ADP-Rezeptor P2Y12
… von Clopidogrel, welches am ADP-Rezeptor P2Y12 wirkt, konnte die Mortalität und Morbidität von kardiovaskulären Ereignissen signifikant gesenkt werden. Der P2Y12 gehört als G-Protein-gekoppelter Rezeptor (GPCR) zur größten Gruppe membranständiger Rezeptoren, welche durch ihr ubiquitäres …
-
Biochemische Charakterisierung des ADP-Rezeptors P2Y12 und pharmakologische Therapiekontrolle von Thrombozytenfunktionshemmern
… die Phospholipase D als ein neuer Effektor des P2Y12 nachgewiesen werden, deren Stimulierung wahrscheinlich zur Degranulierung von Thrombozyten führt. Dieser Mechanismus könnte der Entscheidende sein, der der essentiellen Rolle des Gi-Proteins bei der Stimulation der Sekretion und der …
-
P2Y12-dependent modulation of ADP-evoked calcium responses in human monocytes
The Gi-coupled, ADP-activated P2Y12 receptor is well-characterised as playing a key role in platelet activation via crosstalk with P2Y1. A crucial aspect of P2Y12-P2Y1 crosstalk in platelets involves ADP-induced intracellular calcium (Ca2+) mobilisation, however there is limited knowledge on the …
-
Interactions between aspirin and P2Y12 receptor antagonists in ischaemic heart disease
… of aspirin 75 mg once daily (OD) and the P2Y12 inhibitor ticagrelor represents the current standard antiplatelet treatment for acute coronary syndromes (ACS). Prolonged therapy is indicated in patients at high risk of ischaemic events but low risk of bleeding, though varying aspirin dose …
-
P2Y1-P2Y12 receptor heterodimers : novel insights from microglial cell signalling and computational approaches
P2Y1 and P2Y12 receptors are class A G protein-coupled receptors and previous studies in theKennedy lab suggested that they may physically interact to form functional heterodimers orpossibly higher order oligomers. Little is known, however, about their properties. The aim ofthis project, therefore, …
-
Intracellular signal transduction and modulation of P2Y12 receptor signaling in health and disease
… our findings were likely to be relevant to other P2Y12 receptor blockers.
-
DOES THE INHIBITION OF P2Y12 INHIBIT THE PRODUCTION OF THROMBOXANE A2 BY PLATELETS?
… A2 (TxA2) production, and an antagonist of the P2Y12 receptor for ADP. Based on the recent observation that P2Y12 antagonists also inhibit the platelet production of TxA2, it has been suggested that patients with ACS might be safely treated with P2Y12 antagonists only. However, the observation …
-
Der Einfluss von Leukozyten und body mass index auf die P2Y12-vermittelte Thrombozytenaggregation
… 21 Patienten. In Leukozyten konnte RNA für den P2Y12-Rezeptor nachgewiesen werden. Demzufolge besteht die Möglichkeit, dass Leukozyten P2Y12-Rezeptoren exprimieren und hierüber Clopidogrel nicht nur die Thrombozyten-Leukozyten-Interaktion beeinflusst, sondern unmittelbar auf Leukozyten wirkt. …
-
Desenvolvimento, identificação e modificação estrutural in silico de compostos antitrombóticos inibidores da proteína P2Y12
The discovery of bioactive molecules has been driven by computational approaches and rational strategies, such as Fragment-Based Drug Design (FBDD) and fragment growing techniques. In the context of cardiovascular diseases, membrane-bound therapeutic targets are consolidated as vital for the …
-
Schnelle und reversible Reduktion der Thrombozytenaktivierung bei Diabetes durch den neuartigen P2Y12-Antagonisten AZD6140 (Ticagrelor)
… Untersuchungen über die Auswirkungen des P2Y12-Rezeptor-Antagonisten AZD6140 (Ticagrelor) auf die Plättchenfunktionen diabetischer Ratten. AZD6140 ist ein reversibler, direkter, potenter und oraler Inhibitor des P2Y12-Rezeptors. AZD6140 reduziert als Einzeldosis von 5 mg/ kg Körpergewicht …
-
Comparative Effectiveness And Safety Of P2Y12 Inhibitors In The Secondary Prophylaxis Of Acute Coronary Syndrome
… revascularization. Therefore, treatment with P2Y12 receptor antagonists and aspirin, widely known as dual antiplatelet therapy (DAPT), is strongly recommended as secondary prophylaxis following revascularization. DAPT has been shown to be effective at reducing recurrent events and …
-
Characterising the molecular pharmacology of ligand-dependent and -independent activity of the platelet P2Y12 receptor
… and more specifically targeting the platelet P2Y12 receptor <br/>(P2Y12R), is the gold-standard clinical treatment for ACS patients. Recent studies have demonstrated that P2Y12R exhibits constitutive activity (CA), and hence anti-P2Y12R blockers, such as ticagrelor, have been re-defined as …
-
The Role of the P2Y12 Receptor in the Vessel Wall Response to Injury and Inflammation
… actions on leukocytes and the endothelium. The P2Y12 receptor is responsible for amplifying and sustaining platelet activation. As a result, P2Y12 inhibitors, such as ticagrelor and clopidogrel, form an essential component of acute coronary syndrome treatment in preventing thrombotic events. …
-
Identifizierung von agonistischen und invers agonistischen Eigenschaften determinierender Strukturen in Liganden am ADP-Rezeptor P2Y12
… Eigenschaften von Liganden am ADP-Rezeptor P2Y12. Dazu wurde eine Bibliothek systematisch veränderter Purinverbindungen am Wildtyp-P2Y12 (WT) mit und ohne ADP und an 28 konstitutiv aktiven P2Y12-Mutanten getestet. Dies ermöglichte die pharmakologische Zuordnung der Substanzen als Agonist, …
-
Defining the Molecular Mechanisms of Constitutive Activity and Inverse Agonism at the P2Y12 G-protein Coupled Receptor
… drugs, and more specifically purinergic P2Y12 G-protein coupled receptor (P2Y12R) targeting drugs, are a mainstay therapy for treatment of ACS and CVD. Despite its tractable clinical importance, the molecular pharmacology of the P2Y12R remains poorly defined. Although originally classed …
Page 1 of 7